The study will test the Verily Study Watch. Credit: Verily.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a US-based non-profit organisation, has partnered with Verily Life Sciences, a unit of Alphabet, to study the use of digital health tools for gaining better insights into Parkinson’s disease.

Verily and MJFF will test wearable devices, specifically the Verily Study Watch, on more than 800 participants in the MJFF-led Parkinson’s Progression Markers Initiative (PPMI).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-sensor, investigational Verily Watch continuously collects data on movement, along with different physiologic and environmental measures.

“The companies will provide the raw and curated data to qualified researchers to help advance independent studies and drive knowledge for the development of therapeutics to treat the disease.”

Being carried out at 33 clinical centres, PPMI is a longitudinal study designed to collect clinic-based data and multiple biosamples, which will be combined with the data captured by the Study Watch.

During the two-year study, the partners intend to identify signals and biomarkers of Parkinson’s.

The companies will provide the raw and curated data to qualified researchers to help advance independent studies and drive knowledge for the development of therapeutics to treat the disease.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Verily Clinical Neurology head William Marks said: “These results are urgently needed across many neurological disorders, including Parkinson’s disease.

“By capturing a wealth of data through studies such as PPMI and by deploying technology such as our Study Watch, we aim to build frameworks of multi-dimensional data of value to researchers, clinicians, and data scientists.”

Verily and MJFF also partnered under the Accelerating Medicines Partnership Parkinson’s disease (AMP PD) programme aimed at determining the molecular fingerprint of the disease.

In addition, the companies have worked together to advance Verily’s Liftware range developed for people living with hand tremors or limited mobility.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact